15.53
-0.27 (-1.71%)
| 前收盘价格 | 15.80 |
| 成交量 | 1,083,259 |
| 预期市盈率 (P/E Forward) | 24.69 |
| 价格/销量 (P/S) | 2.98 |
| 股市价格/股市净资产 (P/B) | 2.39 |
| 52周波幅 | |
| 股息率 (DY TTM) | 0.30% |
| 营业毛利率 | 11.16% |
| 营业利益率 (TTM) | 13.97% |
| 稀释每股收益 (EPS TTM) | 0.540 |
| 季度收入增长率 (YOY) | 8.70% |
| 季度盈利增长率 (YOY) | 40.90% |
| 总债务/股东权益 (D/E MRQ) | 27.86% |
| 流动比率 (MRQ) | 1.83 |
| 营业现金流 (OCF TTM) | 184.02 M |
| 杠杆自由现金流 (LFCF TTM) | -113.47 M |
| 资产报酬率 (ROA TTM) | 4.88% |
| 股东权益报酬率 (ROE TTM) | 9.14% |
新闻情绪
-
Broader Biologics Growth Strengthens Stevanato’s (STVN) Long-Term Outlook
10 Nov, 12:47PM
-
Stevanato Group (STVN) Could Be 42% Undervalued Following Q3 Earnings
04 Nov, 4:12AM
-
Stevanato Group SpA (STVN) (Q3 2026) Earnings Call Highlights: Revenue Climbs 8% as Non-GLP ...
03 Nov, 3:07PM
-
Stevanato Group (STVN) Faces Legal Investigation Over GLP 1 Disclosure
04 Nov, 6:15AM
-
Why Stevanato Group Bears Were Right Before The Drop
04 Nov, 4:10PM
AIStockmoo 评分
| 价值 30% | 0.7 |
| 来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 | NA |
| 相对估值 参考 | NA |
| 隐含增长 参考 | NA |
| 低于其一贯估值。 参考 | |
| 负债低。短期流动性充足。现金流为负。 参考 | |
| 资本回报低于资本成本。资本回报下降。 参考 | |
| 时机 30% | -3.5 |
| 来自我们对走势图的 AI 技术分析。 参考 | NA |
| 过去一年呈下降趋势。股价远低于52周高点。 参考 | |
| 下降趋势:股价位于均线之下,均线向下。股价接近均线。下跌日成交量较大。近期突破阻力位尚未获得确认。 参考 | |
| 近期出现看涨反转形态:看涨吞没。 参考 | |
| 低于中期趋势线。 参考 | |
| 市场情绪 20% | 0.1 |
| 近期没有目标价,因此依据目标价的调整方向。 参考 | |
| 近期新闻好坏参半或中性。 参考 | |
| 聪明钱 20% | 2.1 |
| 内部人士近期净买入。 参考 | |
| 机构在最新13F申报中净+12.52%的股份:67家增持,69家减持(截至30 Sep 2026的季度)。 参考 | |
| 市场和行业状况中性。 | |
| 市场环境偏谨慎。 参考 | |
| 行业表现优于大市。 | |
| 各支柱方向不一,评分因此减弱。 | |
| 不计入评分 | |
| 股价低于其52周平均水平。5年来下跌。 参考 | |
| 短、中、长期趋势均向下。短期动能下降。 参考 | |
| 股价处于支撑位与阻力位之间。 参考 | |
| 最终评分 | -0.33 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Instruments & Supplies (US) | 混合的 | 混合的 |
| Medical Instruments & Supplies (全球的) | 混合的 | 混合的 | |
| 股票 | Stevanato Group S.p.A. | 混合的 | 看涨 |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B |
|---|---|---|---|---|
| STVN | - | 0.30% | - | 2.39 |
| ALC | - | 0.49% | - | 1.64 |
| RMD | - | 1.08% | - | 5.66 |
| BDX | - | 2.20% | - | 2.41 |
| WST | - | 0.37% | - | 9.67 |
| BLCO | - | - | - | 1.17 |
|
Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America. |
|
| 部门 | Healthcare |
| 行业 | Medical Instruments & Supplies |
| 投资方式 | Mid Growth |
| 内部持股比例 | 1.68% |
| 机构持股比例 | 112.67% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Nicholas Company, Inc. | 30 Sep 2026 | 743,799 |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| MOREL DONALD E JR | 13.57 | - | 25,000 | 339,250 |
| 累积净数量 | 25,000 | |||
| 累积净值 ($) | 339,250 | |||
| 累积平均购买 ($) | 13.57 | |||
| 累积平均卖出 ($) | - | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| MOREL DONALD E JR | 董事 | 06 Nov 2026 | 买 (+) | 25,000 | 13.57 | 339,250 |
机构
机构持股比例: 94.54%
| 持仓变动 | 机构数 | 股数 |
|---|---|---|
| 增持 | 67 | 8,329,131 |
| 减持 | 69 | 6,219,678 |
| 新建仓 | 28 | 5,656,951 |
| 清仓 | 23 | 1,508,891 |
来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。
| 日期 | 类型 | 细节 |
|---|---|---|
| 16 Nov 2026 | Yahoo Finance |
Stevanato Group to Participate in Upcoming Investor Conferences
PIOMBINO DESE, Italy, November 16, 2026--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in three upcoming… |
| 10 Nov 2026 | Yahoo Finance |
Broader Biologics Growth Strengthens Stevanato’s (STVN) Long-Term Outlook
Cooper Investors, an investment management firm, released its third-quarter 2026 investor letter for “Cooper Investors Global Equities Fund (Unhedged)”. The letter can be downloaded here. The Fund returned 0.50% net of fees in the quarter, driven by Compounding and Real Asset investments, partially… |
| 04 Nov 2026 | Yahoo Finance |
Why Stevanato Group Bears Were Right Before The Drop
Stevanato Group kept reporting healthy headlines, with Q4 and Q1 updates pointing to solid revenue growth, stronger high-value solutions and reaffirmed guidance. Holding Stevanato Group over the past year would have meant a 42.8% loss, including dividends. If you had bought in believing GLP-1… |
| 04 Nov 2026 | Yahoo Finance |
Stevanato Group (STVN) Faces Legal Investigation Over GLP 1 Disclosure
Stevanato Group (NYSE: STVN) faces a pending legal investigation into its disclosures after revising its GLP-1-related volume outlook. Law firm SueWallSt is examining whether Stevanato Group complied with U.S. securities disclosure rules following guidance on lower GLP-1 volumes. The probe focuses… |
| 04 Nov 2026 | Yahoo Finance |
Stevanato Group (STVN) Could Be 42% Undervalued Following Q3 Earnings
Stevanato Group (STVN) just posted its third quarter 2026 earnings, reporting sales of €326.1 million and net income of €41.8 million. These results give investors fresh numbers to reassess the stock. Despite the solid Q3 report and the Aptar Pharma collaboration announced in late October… |
| 04 Nov 2026 | Yahoo Finance |
Stevanato Group Q3 Earnings Call Highlights
Stevanato Group (NYSE:STVN) reported third-quarter 2026 revenue growth of 8% to €326.1 million, supported by continued expansion in its biopharmaceutical and diagnostic solutions business despite weaker demand tied to GLP-1 therapies and a decline in its engineering segment. Chairman and Chief Exec… |
| 03 Nov 2026 | Yahoo Finance |
Stevanato Group S.p.A. Q3 2026 Earnings Call Summary
Moby summary of Stevanato Group S.p.A.'s Q3 2026 earnings call… |
| 03 Nov 2026 | Yahoo Finance |
Stevanato (STVN) Q3 2026 Earnings Call Transcript
Biologics demand held firm while GLP-1 volumes shape the 2027 outlook. |
| 03 Nov 2026 | Yahoo Finance |
Stevanato Group SpA (STVN) (Q3 2026) Earnings Call Highlights: Revenue Climbs 8% as Non-GLP ...
Stevanato Group SpA (STVN) delivered solid Q3 2026 organic growth and margin expansion while flagging a temporary, single-customer GLP-1 volume decline expected to moderate 2027 growth. |
| 03 Nov 2026 | Yahoo Finance |
Stevanato Group (STVN) Surpasses Q3 Earnings and Revenue Estimates
Stevanato (STVN) delivered earnings and revenue surprises of +5.88% and +3.14%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 03 Nov 2026 | Yahoo Finance |
Stevanato: Q3 Earnings Snapshot
PADUA, Italy (AP) — PADUA, Italy (AP) — Stevanato Group SpA (STVN) on Tuesday reported third-quarter earnings of $48.The Padua, Italy-based company said it had profit of 17 cents per share. |
| 03 Nov 2026 | Yahoo Finance |
Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026
PIOMBINO DESE, Italy, November 03, 2026--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of… |
| 28 Oct 2026 | Yahoo Finance |
Stevanato Group S.p.A. (STVN) Rallies on 2Q26 Revenue Growth and EBITDA Margin Expansion
Conestoga Capital Advisors, an asset management company, released its third-quarter 2026 investor letter. The letter can be downloaded here. In 2026, Small Caps initially outperformed but faced challenges in the third quarter, marked by the Russell 2000 Growth Index’s -9.4% decline versus the S&P… |
| 27 Oct 2026 | Yahoo Finance |
Aptar Pharma and Stevanato Group Collaborate to Help Accelerate Pre-Filled Syringe System Selection
CRYSTAL LAKE, Ill., October 27, 2026--Aptar Pharma and Stevanato Group Collaborate to Help Accelerate Pre-Filled Syringe System Selection… |
| 27 Oct 2026 | Yahoo Finance |
Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection
PIOMBINO DESE, Italy, October 27, 2026--Stevanato Group S.p.A. (NYSE: STVN) (the "Company"), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced a collaboration with Aptar Pharma… |
| 20 Oct 2026 | Yahoo Finance |
Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026
PIOMBINO DESE, Italy, October 20, 2026--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third… |
| 01 Oct 2026 | Yahoo Finance |
Ensera launches alliance network with SHL Medical, Stevanato Group, Ypsomed, Argonaut and American Injectables
Ensera, a global CDMO specializing in commercialization support for injectable drug programs, has launched the Ensera Alliance Network, bringing together leading device platform and fill-finish specialists to address the complexity of commercializing drug-device combination products. |
| 01 Oct 2026 | Yahoo Finance |
United Therapeutics (UTHR) Moves 12.6% Higher: Will This Strength Last?
United Therapeutics (UTHR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
| 18 Sep 2026 | Yahoo Finance |
electroCore (ECOR) Stock Jumps 6.9%: Will It Continue to Soar?
electroCore (ECOR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
| 显示更多 | ||
| 股息率 (DY TTM) | 0.30% |
| 4年平均股息收益率 | 0.19% |
| 股息支付比率 | 11.52% |
| 除息日 | 公告日期 | 支付日期 | 详情 |
|---|---|---|---|
| 04 Jun 2024 | 10 Apr 2024 | 15 Jul 2024 | 0.0573 现金 |
| 07 Jun 2023 | 05 Apr 2023 | 17 Jul 2023 | 0.0577 现金 |
| 13 Jun 2022 | 11 Apr 2022 | 13 Jul 2022 | 0.0546 现金 |
每年股息收益率
| 年份 | 每年总股息 ($) | 频率/年份 | 收益率 % |
|---|---|---|---|
| 2024 | 0.057 | 1 | 0.26 |
| 2023 | 0.058 | 1 | 0.21 |
| 2022 | 0.055 | 1 | 0.30 |
近期信号 K线形态与EMA交叉
技术形态 中期
AI 技术分析
投资组合